 postop adjuv chemotherapi non-smal cell lung cancer prognost valu dna ploidi post-recurr surviv eighty-six patient non-smal cell lung cancer cur oper chemotherapi group adjuv chemotherapi group patient cisplatin-bas combin chemotherapi week oper averag cycl chemotherapi cycl trial evid improv surviv recurr treat patient multivari analysi prognost variabl import factor patholog stage diseas second dna ploidi primari tumor histolog squamou non-squam cell carcinoma trend surviv signific factor total patient recurr patient control adjuv chemotherapi group postrecurr surviv adjuv chemotherapi group control group gener wilcoxon log rank test median surviv time recurr control adjuv therapi group month result dna ploidi primari tumor prognost factor futur trial adjuv therapi furthermor analysi postrecurr surviv adjuv chemotherapi trial overal disease-fre surviv